| Characteristic | MITT population (n = 30) |
| Sex (F/M) (n (%)) | 7 (23)/23 (77) |
| Age (y) (mean (range)) | 62.7 (45–79) |
| Smoking history (current/former) (n (%)) | 14 (47)/6 (53) |
| Pack-years (mean (range)) | 46.4 (12–120) |
| Exacerbations in last year (mean (range)) | |
| Managed without requiring OCS/AB | 0.2 (0–3) |
| Requiring OCS/AB | 0.2 (0–2) |
| Requiring hospitalisation in last year | 0.0 (0–1) |
| FEV1 predicted normal (mean (range)) | 47.1 (27.2 to 66.0) |
| % Reversibility of predicted normal (mean (range)) | 6.78 (−3.1 to 19.9) |
| mMRC dyspnoea score (n (%)) | |
| Grade 2 | 21 (70) |
| Grade 3 | 9 (30) |
| BDI (mean (SD)) | 6.3 (1.73) |
| COPD medication pre-study (n (%)) | 23 (77) |
| Salmeterol | 11 (37) |
| Fluticasone propionate | 10 (33) |
| Budesonide | 5 (17) |
| Beclomethasone | 1 (3) |
| Formoterol | 4 (13) |
| Tiotropium | 11 (37) |
AB, antibiotics; BDI, Baseline Dyspnoea Index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; MITT, modified intent to treat; mMRC, modified Medical Research Council; OCS, oral corticosteroids.